<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03595618</url>
  </required_header>
  <id_info>
    <org_study_id>GLPG1972-CL-201</org_study_id>
    <secondary_id>2017-004581-10</secondary_id>
    <secondary_id>U1111-1205-0321</secondary_id>
    <nct_id>NCT03595618</nct_id>
  </id_info>
  <brief_title>A Study to Assess Efficacy and Safety of GLPG1972/S201086 in Participants With Knee Osteoarthritis</brief_title>
  <acronym>Roccella</acronym>
  <official_title>Efficacy and Safety of 3 Doses of S201086/GLPG1972 Administered Orally Once Daily in Patients With Knee Osteoarthritis. A 52-week International, Multi-regional, Multi-center, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galapagos NV</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut de Recherches Internationales Servier</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Galapagos NV</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a phase 2, 52-week international, multi-regional, multi-center, randomized,&#xD;
      double-blind, placebo-controlled dose-ranging study for the treatment of osteoarthritis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 14, 2018</start_date>
  <completion_date type="Actual">July 14, 2020</completion_date>
  <primary_completion_date type="Actual">July 14, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Cartilage Thickness of the cMTFC as Assessed by qMRI on the Target Knee to Week 52</measure>
    <time_frame>Baseline, Week 52</time_frame>
    <description>Reduction in cartilage loss was assessed by cartilage thickness as measured in the medial cMTFC of the target knee using qMRI.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Were Osteoarthritis (OA) Structural Progressors Based on Cartilage Thickness in the cMTFC Assessed by qMRI on the Target Knee</measure>
    <time_frame>Week 52</time_frame>
    <description>A &quot;structural progressor&quot; was defined as a participant who had an 8% cartilage loss in cMTFC. Number of participants who met the criteria of &quot;structural progressor&quot; at Week 52 are provided.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Total Score and Subscales Scores for Pain, Function, and Stiffness to Week 52</measure>
    <time_frame>Baseline, Week 52</time_frame>
    <description>Western Ontario and McMaster Universities Osteoarthritis Index is a questionnaire designed to assess health status and health outcomes in participants with OA of the knee. The questionnaire contains 24 questions targeting areas of pain, stiffness, and physical function. Pain subscale includes 5 items rated on a Likert scale of 0 (none) to 4 (extreme) with a total range of 0-20 with higher scores indicating worse symptoms and function. Stiffness subscale includes 2 items rated on a Likert scale of 0 (none) to 4 (extreme) with a total range of 0-8 with higher scores indicating worse symptoms and function. Physical function subscale includes 17 items rated on a Likert scale of 0 (none) to 4 (extreme) with a total range of 0-68 with higher scores indicating worse symptoms and function. The total score is the sum of all subscales (range: 0 to 96) with higher scores indicating worse symptoms and function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Pain Assessment in the Target Knee as Measured by Visual Analog Scale (VAS) to Week 52</measure>
    <time_frame>Baseline, Week 52</time_frame>
    <description>The participant was asked &quot;how would you rate the pain felt in the selected knee within the last 48 hours?&quot;. The participants rated the pain by marking the level of pain on a 100-mm VAS, with 0 being no pain and 100 being extreme pain. Higher score indicated higher pain intensity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Patient Global Assessment (PGA) of Disease Activity as Measured by VAS to Week 52</measure>
    <time_frame>Baseline, Week 52</time_frame>
    <description>The participant was asked &quot;Considering all the ways in which your knee osteoarthritis affects you, please rate on this 100 mm scale how well you are doing today&quot;. The participants rated the disease activity by marking on a 100-mm VAS, with 0 being no pain and 100 being extreme pain. Higher score indicated higher disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Were Responders Based on the Outcome Measures in Rheumatology - Osteoarthritis Research Society International (OMERACT-OARSI) Criteria</measure>
    <time_frame>Week 52</time_frame>
    <description>OMERACT-OARSI criteria involves improvement based on WOMAC pain and function subscales and PGA. The responders according to OMERACT-OARSI criteria were participants who had:&#xD;
A high improvement in pain or in function ≥ 50% and absolute change ≥ 20, OR&#xD;
Improvement in at least 2 of the 3 following:&#xD;
Pain ≥ 20% and absolute change ≥ 10&#xD;
Function ≥ 20% and absolute change ≥ 10&#xD;
Patient's global assessment ≥ 20% and absolute change ≥ 10.&#xD;
WOMAC pain subscale score: range of 0 to 20, higher scores indicating more pain,&#xD;
WOMAC physical function subscale score: range of 0 to 68, higher scores indicating worse physical function),&#xD;
PGA: The participant was asked &quot;Considering all the ways in which your knee osteoarthritis affects you, please rate on this 100 mm scale how well you are doing today&quot;. The participants rated disease activity by marking on a 100-mm VAS, with 0 being no pain and 100 being extreme pain. Higher score indicated higher disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Cartilage Thickness of the Total Tibiofemoral Compartment (tTFC) of the Target Knee by qMRI to Week 52</measure>
    <time_frame>Baseline, Week 52</time_frame>
    <description>Reduction of cartilage loss was measured by cartilage thickness of the tTFC of the target knee using qMRI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Bone Area of the Medial Femoral Condyle Surface of the Target Knee by qMRI to Week 28</measure>
    <time_frame>Baseline, Week 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Bone Area of the Medial Femoral Condyle Surface of the Target Knee by qMRI to Week 52</measure>
    <time_frame>Baseline, Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Joint Space Width (JSW) of the Target Knee to Week 52</measure>
    <time_frame>Baseline, Week 52</time_frame>
    <description>The JSW is the space measured between the 2 bones in the knee joint and this is assessed by x-ray.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Have Used at Least 1 Systemic Analgesic During the Study</measure>
    <time_frame>Baseline up to Week 52</time_frame>
    <description>Systemic analgesics included anti-inflammatory and anti-rheumatic products; analgesics; anti-diarrheals, intestinal, anti-inflammatory/anti-infective agents; and drugs for functional gastrointestinal disorders.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentrations of GLPG1972</measure>
    <time_frame>Pre-dose at Weeks 4, 12, and 52; Pre-dose and one post-dose sample (2-4 hours interval) at Week 28; one post dose sample (interval 4-8 hours) at Week 40</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-emergent Adverse Event (TEAE)</measure>
    <time_frame>Baseline up to 2-weeks after last dose of IMP (up to Week 54)</time_frame>
    <description>TEAEs were defined as all adverse events (AEs) that occurred:&#xD;
between first IMP intake date (included) and last visit of participant, or&#xD;
before first IMP intake date and that worsened (in terms of intensity) or became serious according to investigator opinion between first IMP intake date (included) and last visit of participant.&#xD;
Number of participants with at least 1 TEAE (serious or non-serious) are reported.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">932</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>GLPG1972 75 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 1 film-coated tablet of GLPG1972 75 mg and 3 GLPG1972 matching placebo tablets, orally once daily for 52 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GLPG1972 150 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 2 film-coated tablets of GLPG1972 75 mg (total dose 150 mg) and 2 GLPG1972 matching placebo tablets, orally once daily for 52 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GLPG1972 300 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 4 film-coated tablets of GLPG1972 75 mg (total dose 300 mg), orally once daily for 52 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received 4 film-coated tablets of GLPG1972 matching placebo, orally once daily for 52 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLPG1972</intervention_name>
    <description>Film-coated tablets of GLPG1972 for oral use.</description>
    <arm_group_label>GLPG1972 150 mg</arm_group_label>
    <arm_group_label>GLPG1972 300 mg</arm_group_label>
    <arm_group_label>GLPG1972 75 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Film-coated tablets of matching placebo for oral use.</description>
    <arm_group_label>GLPG1972 150 mg</arm_group_label>
    <arm_group_label>GLPG1972 75 mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male participants or female participants of non-childbearing potential and not&#xD;
             breastfeeding.&#xD;
&#xD;
          -  Body weight &gt; 40 kg, body mass index (BMI) &lt; 40 kg/m^2.&#xD;
&#xD;
          -  Diagnosed for knee osteoarthritis based on clinical and radiological criteria of the&#xD;
             American College of Rheumatology.&#xD;
&#xD;
          -  History of knee pain for at least 6 months and on the majority of days (&gt; 50%) during&#xD;
             the preceding month.&#xD;
&#xD;
          -  Symptom severity defined by a pain ≥ 40 mm and ≤ 90 mm on visual analogue scale (VAS,&#xD;
             100 mm) at screening and inclusion visits.&#xD;
&#xD;
          -  Documented need for symptomatic as needed-treatment for osteoarthritis (OA) in the&#xD;
             target knee with systemic non-steroidal anti-inflammatory drugs (NSAIDs) and/or other&#xD;
             analgesics&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe clinical knee malalignment according to the investigator.&#xD;
&#xD;
          -  Knee prosthesis already implanted (&lt; 1 year) or not well-tolerated (contralateral&#xD;
             side).&#xD;
&#xD;
          -  Knee prosthesis already foreseen within the study period (whichever side).&#xD;
&#xD;
          -  Hip prosthesis recently implanted (&lt; 1 year) or foreseen within the study period&#xD;
             (whichever side).&#xD;
&#xD;
          -  Previous osteotomy on the inferior limbs (whichever side).&#xD;
&#xD;
          -  Surgical operation on the target knee within the 12 months prior to the screening&#xD;
             visit or planned during the study.&#xD;
&#xD;
          -  Diagnostic arthroscopy of the target knee within the 6 months prior to the screening&#xD;
             visit or planned during the study.&#xD;
&#xD;
          -  Other pathologies affecting the target knee.&#xD;
&#xD;
          -  Any contraindication to magnetic resonance imaging (MRI) including the inability to&#xD;
             undergo a knee MRI exam because of inability to fit in the scanner or knee coil.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Galapagos Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Galapagos NV</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Central Research Associates, Inc.</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Achieve Clinical Research, LLC</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elite Clinical Studies</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hope Research Institute, LLC - Arizona</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arizona Research Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85053</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Consortium Arizona</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samy Metyas MD, Inc - Covina Arthritis Clinic</name>
      <address>
        <city>Covina</city>
        <state>California</state>
        <zip>91723</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TriWest Research Associates, LLC</name>
      <address>
        <city>El Cajon</city>
        <state>California</state>
        <zip>92020</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BioSolutions Clinical Research Center</name>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <zip>91942</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Helm Center for Pain Management</name>
      <address>
        <city>Laguna Hills</city>
        <state>California</state>
        <zip>92637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Artemis Institute for Clinical Research - San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Artemis Institute for Clinical Research - San Marcos</name>
      <address>
        <city>San Marcos</city>
        <state>California</state>
        <zip>92078</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Encompass Clinical Research</name>
      <address>
        <city>Spring Valley</city>
        <state>California</state>
        <zip>91978</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Musculoskeletal Care - Yale Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Avail Clinical Research, LLC</name>
      <address>
        <city>DeLand</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Physiology Associates Clinical Study Center</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Awareness, Inc</name>
      <address>
        <city>Jupiter</city>
        <state>Florida</state>
        <zip>33458</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bioclinica Research</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stedman Clinical Trials, LLC</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Compass Research, LLC</name>
      <address>
        <city>The Villages</city>
        <state>Florida</state>
        <zip>32162</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Injury Care Research, LLC</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Millennium Pain Center - Bloomington</name>
      <address>
        <city>Bloomington</city>
        <state>Illinois</state>
        <zip>61704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medisphere Medical Research Center</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47714</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phoenix Medical Reasearch</name>
      <address>
        <city>Prairie Village</city>
        <state>Kansas</state>
        <zip>66208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Kentucky Research Associates, Inc.</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40509</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medpharmics</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center for Rheumatology and Bone Research</name>
      <address>
        <city>Wheaton</city>
        <state>Maryland</state>
        <zip>20902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Consortium Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NY Scientific</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rochester Clinical Research, Inc.</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Upstate Clinical Research Associates</name>
      <address>
        <city>Williamsville</city>
        <state>New York</state>
        <zip>14221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lillestol Research, LCC</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Optimed Research, LTD</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altoona Center for Clinical Research</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pioneer Research Solutions Inc.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77099</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diagnostics Research Group</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Research</name>
      <address>
        <city>West Jordan</city>
        <state>Utah</state>
        <zip>84088</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charlottesville Medical Research Center, LCC</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Research of Hampton Roads, Inc. - Newport News</name>
      <address>
        <city>Newport News</city>
        <state>Virginia</state>
        <zip>23606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Associates of Tidewater</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 11, 2018</study_first_submitted>
  <study_first_submitted_qc>July 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 23, 2018</study_first_posted>
  <results_first_submitted>April 20, 2021</results_first_submitted>
  <results_first_submitted_qc>April 20, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 12, 2021</results_first_posted>
  <last_update_submitted>July 27, 2021</last_update_submitted>
  <last_update_submitted_qc>July 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 9, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/18/NCT03595618/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 29, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/18/NCT03595618/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The first participant was screened on 14 August 2018. The last study visit occurred on 14 July 2020. Due to the exceptional circumstances in relation to the COVID-19 pandemic, the Sponsor decided in accordance with competent regulatory authorities' guidelines to implement some precautionary measures in order to mitigate the risk of infection.</recruitment_details>
      <pre_assignment_details>A total of 3319 participants were screened and 932 participants were randomized and 931 participants were treated.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>GLPG1972 75 mg</title>
          <description>Participants received 1 film-coated tablet of GLPG1972 75 mg and 3 GLPG1972 matching placebo tablets, orally once daily for 52 weeks.</description>
        </group>
        <group group_id="P2">
          <title>GLPG1972 150 mg</title>
          <description>Participants received 2 film-coated tablets of GLPG1972 75 mg (total dose 150 mg) and 2 GLPG1972 matching placebo tablets, orally once daily for 52 weeks.</description>
        </group>
        <group group_id="P3">
          <title>GLPG1972 300 mg</title>
          <description>Participants received 4 film-coated tablets of GLPG1972 75 mg (total dose 300 mg), orally once daily for 52 weeks.</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>Participants received 4 film-coated tablets of GLPG1972 matching placebo, orally once daily for 52 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="234"/>
                <participants group_id="P2" count="231"/>
                <participants group_id="P3" count="233"/>
                <participants group_id="P4" count="234"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="234"/>
                <participants group_id="P2" count="231"/>
                <participants group_id="P3" count="232"/>
                <participants group_id="P4" count="234"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="191"/>
                <participants group_id="P2" count="191"/>
                <participants group_id="P3" count="177"/>
                <participants group_id="P4" count="200"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="40"/>
                <participants group_id="P3" count="56"/>
                <participants group_id="P4" count="34"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="20"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Miscellaneous</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Modified Randomised Set (mRS): All included participants to whom a therapeutic unit was randomly assigned using the interactive web response system.</population>
      <group_list>
        <group group_id="B1">
          <title>GLPG1972 75 mg</title>
          <description>Participants received 1 film-coated tablet of GLPG1972 75 mg and 3 GLPG1972 matching placebo tablets, orally once daily for 52 weeks.</description>
        </group>
        <group group_id="B2">
          <title>GLPG1972 150 mg</title>
          <description>Participants received 2 film-coated tablets of GLPG1972 75 mg (total dose 150 mg) and 2 GLPG1972 matching placebo tablets, orally once daily for 52 weeks.</description>
        </group>
        <group group_id="B3">
          <title>GLPG1972 300 mg</title>
          <description>Participants received 4 film-coated tablets of GLPG1972 75 mg (total dose 300 mg), orally once daily for 52 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>Participants received 4 film-coated tablets of GLPG1972 matching placebo, orally once daily for 52 weeks.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="234"/>
            <count group_id="B2" value="231"/>
            <count group_id="B3" value="233"/>
            <count group_id="B4" value="234"/>
            <count group_id="B5" value="932"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="234"/>
                    <count group_id="B2" value="231"/>
                    <count group_id="B3" value="233"/>
                    <count group_id="B4" value="234"/>
                    <count group_id="B5" value="932"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.9" spread="7.5"/>
                    <measurement group_id="B2" value="63.2" spread="7.2"/>
                    <measurement group_id="B3" value="62.1" spread="7.4"/>
                    <measurement group_id="B4" value="63.3" spread="7.1"/>
                    <measurement group_id="B5" value="62.9" spread="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="234"/>
                    <count group_id="B2" value="231"/>
                    <count group_id="B3" value="233"/>
                    <count group_id="B4" value="234"/>
                    <count group_id="B5" value="932"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="164"/>
                    <measurement group_id="B2" value="165"/>
                    <measurement group_id="B3" value="154"/>
                    <measurement group_id="B4" value="163"/>
                    <measurement group_id="B5" value="646"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="66"/>
                    <measurement group_id="B3" value="79"/>
                    <measurement group_id="B4" value="71"/>
                    <measurement group_id="B5" value="286"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="234"/>
                    <count group_id="B2" value="231"/>
                    <count group_id="B3" value="233"/>
                    <count group_id="B4" value="234"/>
                    <count group_id="B5" value="932"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="53"/>
                    <measurement group_id="B5" value="193"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="182"/>
                    <measurement group_id="B2" value="179"/>
                    <measurement group_id="B3" value="197"/>
                    <measurement group_id="B4" value="181"/>
                    <measurement group_id="B5" value="739"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="234"/>
                    <count group_id="B2" value="231"/>
                    <count group_id="B3" value="233"/>
                    <count group_id="B4" value="234"/>
                    <count group_id="B5" value="932"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="32"/>
                    <measurement group_id="B5" value="121"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="25"/>
                    <measurement group_id="B5" value="96"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="167"/>
                    <measurement group_id="B2" value="177"/>
                    <measurement group_id="B3" value="168"/>
                    <measurement group_id="B4" value="171"/>
                    <measurement group_id="B5" value="683"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cartilage Thickness of the Central Medial Tibiofemoral Compartment (cMTFC) of the Target Knee</title>
          <description>Cartilage thickness of the cMTFC of the target knee was measured by quantitative magnetic resonance imaging (qMRI)</description>
          <population>Number of participants analyzed included participants with available data of cartilage thickness in the cMTFC at baseline.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="233"/>
                    <count group_id="B2" value="229"/>
                    <count group_id="B3" value="231"/>
                    <count group_id="B4" value="234"/>
                    <count group_id="B5" value="927"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.25316" spread="0.75857"/>
                    <measurement group_id="B2" value="3.23101" spread="0.75531"/>
                    <measurement group_id="B3" value="3.33075" spread="0.79839"/>
                    <measurement group_id="B4" value="3.18554" spread="0.81513"/>
                    <measurement group_id="B5" value="3.24996" spread="0.78289"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Cartilage Thickness of the cMTFC as Assessed by qMRI on the Target Knee to Week 52</title>
        <description>Reduction in cartilage loss was assessed by cartilage thickness as measured in the medial cMTFC of the target knee using qMRI.</description>
        <time_frame>Baseline, Week 52</time_frame>
        <population>Analysis was based on the mRS. Overall number of participants analyzed included participants with available data of cartilage thickness in the cMTFC at baseline and Week 52.</population>
        <group_list>
          <group group_id="O1">
            <title>GLPG1972 75 mg</title>
            <description>Participants received 1 film-coated tablet of GLPG1972 75 mg and 3 GLPG1972 matching placebo tablets, orally once daily for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>GLPG1972 150 mg</title>
            <description>Participants received 2 film-coated tablets of GLPG1972 75 mg (total dose 150 mg) and 2 GLPG1972 matching placebo tablets, orally once daily for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>GLPG1972 300 mg</title>
            <description>Participants received 4 film-coated tablets of GLPG1972 75 mg (total dose 300 mg), orally once daily for 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received 4 film-coated tablets of GLPG1972 matching placebo, orally once daily for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Cartilage Thickness of the cMTFC as Assessed by qMRI on the Target Knee to Week 52</title>
          <description>Reduction in cartilage loss was assessed by cartilage thickness as measured in the medial cMTFC of the target knee using qMRI.</description>
          <population>Analysis was based on the mRS. Overall number of participants analyzed included participants with available data of cartilage thickness in the cMTFC at baseline and Week 52.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="162"/>
                <count group_id="O2" value="158"/>
                <count group_id="O3" value="151"/>
                <count group_id="O4" value="172"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.06791" spread="0.20169"/>
                    <measurement group_id="O2" value="-0.09693" spread="0.26839"/>
                    <measurement group_id="O3" value="-0.08545" spread="0.21697"/>
                    <measurement group_id="O4" value="-0.11562" spread="0.27275"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Estimate (Standard Error) of adjusted difference from baseline to last post baseline value between treatment groups means: GLPG1972 dose minus placebo using mixed-effects model for repeated measures (MMRM) including fixed, categorical effects of treatment, region (Asia and Rest of the World), time and treatment-by-time interaction, as well as continuous, fixed covariates of baseline and time-by-baseline interaction preceded by multiple imputation step for participants without post baseline value</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.165</p_value>
            <p_value_desc>Two-sided adjusted p-value taking into account Dunnett adjustment (to be compared to 0.05).</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.04514</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.02465</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.00317</ci_lower_limit>
            <ci_upper_limit>0.09345</ci_upper_limit>
            <estimate_desc>Two-sided 95% confidence interval of the estimate without Dunnett adjustment.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Estimate (Standard Error) of adjusted difference from baseline to last post baseline value between treatment groups means: GLPG1972 dose minus placebo using MMRM including fixed, categorical effects of treatment, region (Asia and Rest of the World), time and treatment-by-time interaction, as well as continuous, fixed covariates of baseline and time-by-baseline interaction preceded by multiple imputation step for participants without post baseline value.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.939</p_value>
            <p_value_desc>Two-sided adjusted p-value taking into account Dunnett adjustment (to be compared to 0.05).</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.01200</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.02585</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.03868</ci_lower_limit>
            <ci_upper_limit>0.06267</ci_upper_limit>
            <estimate_desc>Two-sided 95% confidence interval of the estimate without Dunnett adjustment.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Estimate (Standard Error) of adjusted difference from baseline to last post baseline value between treatment groups means: GLPG1972 dose minus placebo using MMRM including fixed, categorical effects of treatment, region (Asia and Rest of the World), time and treatment-by-time interaction, as well as continuous, fixed covariates of baseline and time-by-baseline interaction preceded by multiple imputation step for participants without post baseline value.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.682</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.02329</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.02536</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.02641</ci_lower_limit>
            <ci_upper_limit>0.07300</ci_upper_limit>
            <estimate_desc>Two-sided 95% confidence interval of the estimate without Dunnett adjustment.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Were Osteoarthritis (OA) Structural Progressors Based on Cartilage Thickness in the cMTFC Assessed by qMRI on the Target Knee</title>
        <description>A &quot;structural progressor&quot; was defined as a participant who had an 8% cartilage loss in cMTFC. Number of participants who met the criteria of &quot;structural progressor&quot; at Week 52 are provided.</description>
        <time_frame>Week 52</time_frame>
        <population>Analysis was based on the mRS. Overall number of participants analyzed included participants with available data of cartilage thickness in the cMTFC at Week 52.</population>
        <group_list>
          <group group_id="O1">
            <title>GLPG1972 75 mg</title>
            <description>Participants received 1 film-coated tablet of GLPG1972 75 mg and 3 GLPG1972 matching placebo tablets, orally once daily for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>GLPG1972 150 mg</title>
            <description>Participants received 2 film-coated tablets of GLPG1972 75 mg (total dose 150 mg) and 2 GLPG1972 matching placebo tablets, orally once daily for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>GLPG1972 300 mg</title>
            <description>Participants received 4 film-coated tablets of GLPG1972 75 mg (total dose 300 mg), orally once daily for 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received 4 film-coated tablets of GLPG1972 matching placebo, orally once daily for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Were Osteoarthritis (OA) Structural Progressors Based on Cartilage Thickness in the cMTFC Assessed by qMRI on the Target Knee</title>
          <description>A &quot;structural progressor&quot; was defined as a participant who had an 8% cartilage loss in cMTFC. Number of participants who met the criteria of &quot;structural progressor&quot; at Week 52 are provided.</description>
          <population>Analysis was based on the mRS. Overall number of participants analyzed included participants with available data of cartilage thickness in the cMTFC at Week 52.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="162"/>
                <count group_id="O2" value="158"/>
                <count group_id="O3" value="151"/>
                <count group_id="O4" value="172"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="25"/>
                    <measurement group_id="O4" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Estimate (Standard Error of log [estimate]) of the adjusted odds ratio between GLPG1972 dose regimen and placebo: between the proportions of participants with response: placebo versus GLPG1972 dose regimen</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.396</p_value>
            <p_value_desc>Two-sided adjusted p-value taking into account Dunnett adjustment (to be compared to 0.05)</p_value_desc>
            <method>Logistic Model</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.47</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.29</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.84</ci_lower_limit>
            <ci_upper_limit>2.58</ci_upper_limit>
            <estimate_desc>Two-sided 95% Confidence Interval of the estimate without Dunnett adjustment</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Estimate (Standard Error of log [estimate]) of the adjusted odds ratio between GLPG1972 dose regimen and placebo: between the proportions of participants with response: placebo versus GLPG1972 dose regimen</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.951</p_value>
            <p_value_desc>Two-sided adjusted p-value taking into account Dunnett adjustment (to be compared to 0.05)</p_value_desc>
            <method>Logistic Model</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.89</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.26</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.53</ci_lower_limit>
            <ci_upper_limit>1.50</ci_upper_limit>
            <estimate_desc>Two-sided 95% Confidence Interval of the estimate without Dunnett adjustment</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Estimate (Standard Error of log [estimate]) of the adjusted odds ratio between GLPG1972 dose regimen and placebo: between the proportions of participants with response: placebo versus GLPG1972 dose regimen</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.985</p_value>
            <p_value_desc>Two-sided adjusted p-value taking into account Dunnett adjustment (to be compared to 0.05)</p_value_desc>
            <method>Logistic Model</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.08</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.27</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.64</ci_lower_limit>
            <ci_upper_limit>1.83</ci_upper_limit>
            <estimate_desc>Two-sided 95% Confidence Interval of the estimate without Dunnett adjustment</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Total Score and Subscales Scores for Pain, Function, and Stiffness to Week 52</title>
        <description>Western Ontario and McMaster Universities Osteoarthritis Index is a questionnaire designed to assess health status and health outcomes in participants with OA of the knee. The questionnaire contains 24 questions targeting areas of pain, stiffness, and physical function. Pain subscale includes 5 items rated on a Likert scale of 0 (none) to 4 (extreme) with a total range of 0-20 with higher scores indicating worse symptoms and function. Stiffness subscale includes 2 items rated on a Likert scale of 0 (none) to 4 (extreme) with a total range of 0-8 with higher scores indicating worse symptoms and function. Physical function subscale includes 17 items rated on a Likert scale of 0 (none) to 4 (extreme) with a total range of 0-68 with higher scores indicating worse symptoms and function. The total score is the sum of all subscales (range: 0 to 96) with higher scores indicating worse symptoms and function.</description>
        <time_frame>Baseline, Week 52</time_frame>
        <population>Analysis was based on mRS. Overall number of participants analyzed included participants with available data of WOMAC score at baseline. Number of participants analyzed for change from baseline to Week 52 included participants with available data of WOMAC score at baseline and Week 52.</population>
        <group_list>
          <group group_id="O1">
            <title>GLPG1972 75 mg</title>
            <description>Participants received 1 film-coated tablet of GLPG1972 75 mg and 3 GLPG1972 matching placebo tablets, orally once daily for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>GLPG1972 150 mg</title>
            <description>Participants received 2 film-coated tablets of GLPG1972 75 mg (total dose 150 mg) and 2 GLPG1972 matching placebo tablets, orally once daily for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>GLPG1972 300 mg</title>
            <description>Participants received 4 film-coated tablets of GLPG1972 75 mg (total dose 300 mg), orally once daily for 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received 4 film-coated tablets of GLPG1972 matching placebo, orally once daily for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Total Score and Subscales Scores for Pain, Function, and Stiffness to Week 52</title>
          <description>Western Ontario and McMaster Universities Osteoarthritis Index is a questionnaire designed to assess health status and health outcomes in participants with OA of the knee. The questionnaire contains 24 questions targeting areas of pain, stiffness, and physical function. Pain subscale includes 5 items rated on a Likert scale of 0 (none) to 4 (extreme) with a total range of 0-20 with higher scores indicating worse symptoms and function. Stiffness subscale includes 2 items rated on a Likert scale of 0 (none) to 4 (extreme) with a total range of 0-8 with higher scores indicating worse symptoms and function. Physical function subscale includes 17 items rated on a Likert scale of 0 (none) to 4 (extreme) with a total range of 0-68 with higher scores indicating worse symptoms and function. The total score is the sum of all subscales (range: 0 to 96) with higher scores indicating worse symptoms and function.</description>
          <population>Analysis was based on mRS. Overall number of participants analyzed included participants with available data of WOMAC score at baseline. Number of participants analyzed for change from baseline to Week 52 included participants with available data of WOMAC score at baseline and Week 52.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="233"/>
                <count group_id="O2" value="230"/>
                <count group_id="O3" value="231"/>
                <count group_id="O4" value="234"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total score: Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="233"/>
                    <count group_id="O2" value="230"/>
                    <count group_id="O3" value="231"/>
                    <count group_id="O4" value="234"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.0" spread="15.2"/>
                    <measurement group_id="O2" value="48.7" spread="15.0"/>
                    <measurement group_id="O3" value="47.0" spread="15.2"/>
                    <measurement group_id="O4" value="48.3" spread="14.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total score: Change from baseline to Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="189"/>
                    <count group_id="O2" value="187"/>
                    <count group_id="O3" value="176"/>
                    <count group_id="O4" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.3" spread="17.7"/>
                    <measurement group_id="O2" value="-16.9" spread="17.7"/>
                    <measurement group_id="O3" value="-16.1" spread="19.8"/>
                    <measurement group_id="O4" value="-18.4" spread="18.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain subscore: Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="233"/>
                    <count group_id="O2" value="230"/>
                    <count group_id="O3" value="231"/>
                    <count group_id="O4" value="234"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.2" spread="3.2"/>
                    <measurement group_id="O2" value="10.0" spread="3.1"/>
                    <measurement group_id="O3" value="9.8" spread="3.1"/>
                    <measurement group_id="O4" value="10.0" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain subscore: Change from baseline to Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="189"/>
                    <count group_id="O2" value="187"/>
                    <count group_id="O3" value="176"/>
                    <count group_id="O4" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.9" spread="4.1"/>
                    <measurement group_id="O2" value="-3.7" spread="4.0"/>
                    <measurement group_id="O3" value="-3.7" spread="4.2"/>
                    <measurement group_id="O4" value="-4.1" spread="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical function subscore: Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="233"/>
                    <count group_id="O2" value="230"/>
                    <count group_id="O3" value="231"/>
                    <count group_id="O4" value="234"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.8" spread="11.2"/>
                    <measurement group_id="O2" value="34.3" spread="11.2"/>
                    <measurement group_id="O3" value="33.0" spread="11.6"/>
                    <measurement group_id="O4" value="34.1" spread="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical function subscore: Change from baseline to Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="189"/>
                    <count group_id="O2" value="187"/>
                    <count group_id="O3" value="176"/>
                    <count group_id="O4" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.2" spread="12.7"/>
                    <measurement group_id="O2" value="-11.9" spread="13.0"/>
                    <measurement group_id="O3" value="-10.9" spread="14.7"/>
                    <measurement group_id="O4" value="-12.7" spread="13.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stiffness subscore: Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="233"/>
                    <count group_id="O2" value="230"/>
                    <count group_id="O3" value="231"/>
                    <count group_id="O4" value="234"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" spread="1.7"/>
                    <measurement group_id="O2" value="4.3" spread="1.7"/>
                    <measurement group_id="O3" value="4.2" spread="1.6"/>
                    <measurement group_id="O4" value="4.2" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stiffness subscore: Change from baseline to Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="189"/>
                    <count group_id="O2" value="187"/>
                    <count group_id="O3" value="176"/>
                    <count group_id="O4" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="2.1"/>
                    <measurement group_id="O2" value="-1.3" spread="2.0"/>
                    <measurement group_id="O3" value="-1.4" spread="2.0"/>
                    <measurement group_id="O4" value="-1.5" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Total score: Estimate (Standard Error) of adjusted difference from baseline to last post baseline value between treatment groups means: placebo minus GLPG1972 dose using MMRM including fixed, categorical effects of treatment, region (Asia and Rest of the World), time and treatment-by-time interaction, as well as continuous, fixed covariates of baseline and time-by-baseline interaction preceded by multiple imputation step for participants without post baseline value.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.467</p_value>
            <p_value_desc>Two-sided adjusted p-value taking into account Dunnett adjustment (to be compared to 0.05).</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-2.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.7</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.6</ci_lower_limit>
            <ci_upper_limit>1.3</ci_upper_limit>
            <estimate_desc>Two-sided 95% Confidence Interval of the estimate without Dunnett adjustment</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Total score: Estimate (Standard Error) of adjusted difference from baseline to last post baseline value between treatment groups means: placebo minus GLPG1972 dose using MMRM including fixed, categorical effects of treatment, region (Asia and Rest of the World), time and treatment-by-time interaction, as well as continuous, fixed covariates of baseline and time-by-baseline interaction preceded by multiple imputation step for participants without post baseline value.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.557</p_value>
            <p_value_desc>Two-sided adjusted p-value taking into account Dunnett adjustment (to be compared to 0.05)</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-1.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.8</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.4</ci_lower_limit>
            <ci_upper_limit>1.5</ci_upper_limit>
            <estimate_desc>Two-sided 95% Confidence Interval of the estimate without Dunnett adjustment.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Total score: Estimate (Standard Error) of adjusted difference from baseline to last post baseline value between treatment groups means: placebo minus GLPG1972 dose using MMRM including fixed, categorical effects of treatment, region (Asia and Rest of the World), time and treatment-by-time interaction, as well as continuous, fixed covariates of baseline and time-by-baseline interaction preceded by multiple imputation step for participants without post baseline value.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.593</p_value>
            <p_value_desc>Two-sided adjusted p-value taking into account Dunnett adjustment (to be compared to 0.05).</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-1.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.8</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.3</ci_lower_limit>
            <ci_upper_limit>1.6</ci_upper_limit>
            <estimate_desc>Two-sided 95% Confidence Interval of the estimate without Dunnett adjustment.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Pain subscore: Estimate (Standard Error) of adjusted difference from baseline to last post baseline value between treatment groups means: placebo minus GLPG1972 dose using MMRM including fixed, categorical effects of treatment, region (Asia and Rest of the World), time and treatment-by-time interaction, as well as continuous, fixed covariates of baseline and time-by-baseline interaction preceded by multiple imputation step for participants without post baseline value.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.776</p_value>
            <p_value_desc>Two-sided adjusted p-value taking into account Dunnett adjustment (to be compared to 0.05).</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.4</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.0</ci_lower_limit>
            <ci_upper_limit>0.4</ci_upper_limit>
            <estimate_desc>Two-sided 95% Confidence Interval of the estimate without Dunnett adjustment.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Pain subscore: Estimate (Standard Error) of adjusted difference from baseline to last post baseline value between treatment groups means: placebo minus GLPG1972 dose using MMRM including fixed, categorical effects of treatment, region (Asia and Rest of the World), time and treatment-by-time interaction, as well as continuous, fixed covariates of baseline and time-by-baseline interaction preceded by multiple imputation step for participants without post baseline value.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.446</p_value>
            <p_value_desc>Two-sided adjusted p-value taking into account Dunnett adjustment (to be compared to 0.05).</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.4</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.2</ci_lower_limit>
            <ci_upper_limit>0.3</ci_upper_limit>
            <estimate_desc>Two-sided 95% Confidence Interval of the estimate without Dunnett adjustment.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Pain subscore: Estimate (Standard Error) of adjusted difference from baseline to last post baseline value between treatment groups means: placebo minus GLPG1972 dose using MMRM including fixed, categorical effects of treatment, region (Asia and Rest of the World), time and treatment-by-time interaction, as well as continuous, fixed covariates of baseline and time-by-baseline interaction preceded by multiple imputation step for participants without post baseline value.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.649</p_value>
            <p_value_desc>Two-sided adjusted p-value taking into account Dunnett adjustment (to be compared to 0.05).</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.4</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.1</ci_lower_limit>
            <ci_upper_limit>0.4</ci_upper_limit>
            <estimate_desc>Two-sided 95% Confidence Interval of the estimate without Dunnett adjustment.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Physical function subscore: Estimate (Standard Error) of adjusted difference from baseline to last post baseline value between treatment groups means: placebo minus GLPG1972 dose using MMRM including fixed, categorical effects of treatment, region (Asia and Rest of the World), time and treatment-by-time interaction, as well as continuous, fixed covariates of baseline and time-by-baseline interaction preceded by multiple imputation step for participants without post baseline value.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.452</p_value>
            <p_value_desc>Two-sided adjusted p-value taking into account Dunnett adjustment (to be compared to 0.05).</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-1.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.3</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.1</ci_lower_limit>
            <ci_upper_limit>0.9</ci_upper_limit>
            <estimate_desc>Two-sided 95% Confidence Interval of the estimate without Dunnett adjustment.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Physical Function subscore: Estimate (Standard Error) of adjusted difference from baseline to last post baseline value between treatment groups means: placebo minus GLPG1972 dose using MMRM including fixed, categorical effects of treatment, region (Asia and Rest of the World), time and treatment-by-time interaction, as well as continuous, fixed covariates of baseline and time-by-baseline interaction preceded by multiple imputation step for participants without post baseline value.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.665</p_value>
            <p_value_desc>Two-sided adjusted p-value taking into account Dunnett adjustment (to be compared to 0.05).</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-1.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.3</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.7</ci_lower_limit>
            <ci_upper_limit>1.3</ci_upper_limit>
            <estimate_desc>Two-sided 95% Confidence Interval of the estimate without Dunnett adjustment.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Physical Function subscore: Estimate (Standard Error) of adjusted difference from baseline to last post baseline value between treatment groups means: placebo minus GLPG1972 dose using MMRM including fixed, categorical effects of treatment, region (Asia and Rest of the World), time and treatment-by-time interaction, as well as continuous, fixed covariates of baseline and time-by-baseline interaction preceded by multiple imputation step for participants without post baseline value.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.598</p_value>
            <p_value_desc>Two-sided adjusted p-value taking into account Dunnett adjustment (to be compared to 0.05).</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-1.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.3</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.9</ci_lower_limit>
            <ci_upper_limit>1.2</ci_upper_limit>
            <estimate_desc>Two-sided 95% Confidence Interval of the estimate without Dunnett adjustment.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Stiffness subscore: Estimate (Standard Error) of adjusted difference from baseline to last post baseline value between treatment groups means: placebo minus GLPG1972 dose using MMRM including fixed, categorical effects of treatment, region (Asia and Rest of the World), time and treatment-by-time interaction, as well as continuous, fixed covariates of baseline and time-by-baseline interaction preceded by multiple imputation step for participants without post baseline value.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.400</p_value>
            <p_value_desc>Two-sided adjusted p-value taking into account Dunnett adjustment (to be compared to 0.05)</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.2</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.6</ci_lower_limit>
            <ci_upper_limit>0.1</ci_upper_limit>
            <estimate_desc>Two-sided 95% Confidence Interval of the estimate without Dunnett adjustment</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Stiffness subscore: Estimate (Standard Error) of adjusted difference from baseline to last post baseline value between treatment groups means: placebo minus GLPG1972 dose using MMRM including fixed, categorical effects of treatment, region (Asia and Rest of the World), time and treatment-by-time interaction, as well as continuous, fixed covariates of baseline and time-by-baseline interaction preceded by multiple imputation step for participants without post baseline value.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.393</p_value>
            <p_value_desc>Two-sided adjusted p-value taking into account Dunnett adjustment (to be compared to 0.05)</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.2</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.6</ci_lower_limit>
            <ci_upper_limit>0.1</ci_upper_limit>
            <estimate_desc>Two-sided 95% Confidence Interval of the estimate without Dunnett adjustment</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Stiffness subscore: Estimate (Standard Error) of adjusted difference from baseline to last post baseline value between treatment groups means: placebo minus GLPG1972 dose using MMRM including fixed, categorical effects of treatment, region (Asia and Rest of the World), time and treatment-by-time interaction, as well as continuous, fixed covariates of baseline and time-by-baseline interaction preceded by multiple imputation step for participants without post baseline value.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.858</p_value>
            <p_value_desc>Two-sided adjusted p-value taking into account Dunnett adjustment (to be compared to 0.05)</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.2</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.5</ci_lower_limit>
            <ci_upper_limit>0.2</ci_upper_limit>
            <estimate_desc>Two-sided 95% Confidence Interval of the estimate without Dunnett adjustment</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Pain Assessment in the Target Knee as Measured by Visual Analog Scale (VAS) to Week 52</title>
        <description>The participant was asked &quot;how would you rate the pain felt in the selected knee within the last 48 hours?&quot;. The participants rated the pain by marking the level of pain on a 100-mm VAS, with 0 being no pain and 100 being extreme pain. Higher score indicated higher pain intensity.</description>
        <time_frame>Baseline, Week 52</time_frame>
        <population>Analysis was based on mRS. Overall number of participants analyzed included participants with available data of VAS at baseline. Number of participants analyzed for change from baseline to Week 52 included participants with available data of VAS at baseline and Week 52.</population>
        <group_list>
          <group group_id="O1">
            <title>GLPG1972 75 mg</title>
            <description>Participants received 1 film-coated tablet of GLPG1972 75 mg and 3 GLPG1972 matching placebo tablets, orally once daily for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>GLPG1972 150 mg</title>
            <description>Participants received 2 film-coated tablets of GLPG1972 75 mg (total dose 150 mg) and 2 GLPG1972 matching placebo tablets, orally once daily for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>GLPG1972 300 mg</title>
            <description>Participants received 4 film-coated tablets of GLPG1972 75 mg (total dose 300 mg), orally once daily for 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received 4 film-coated tablets of GLPG1972 matching placebo, orally once daily for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Pain Assessment in the Target Knee as Measured by Visual Analog Scale (VAS) to Week 52</title>
          <description>The participant was asked &quot;how would you rate the pain felt in the selected knee within the last 48 hours?&quot;. The participants rated the pain by marking the level of pain on a 100-mm VAS, with 0 being no pain and 100 being extreme pain. Higher score indicated higher pain intensity.</description>
          <population>Analysis was based on mRS. Overall number of participants analyzed included participants with available data of VAS at baseline. Number of participants analyzed for change from baseline to Week 52 included participants with available data of VAS at baseline and Week 52.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="234"/>
                <count group_id="O2" value="231"/>
                <count group_id="O3" value="233"/>
                <count group_id="O4" value="234"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="234"/>
                    <count group_id="O2" value="231"/>
                    <count group_id="O3" value="233"/>
                    <count group_id="O4" value="234"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.3" spread="11.4"/>
                    <measurement group_id="O2" value="63.8" spread="11.5"/>
                    <measurement group_id="O3" value="63.3" spread="12.1"/>
                    <measurement group_id="O4" value="63.5" spread="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline to Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="191"/>
                    <count group_id="O2" value="185"/>
                    <count group_id="O3" value="178"/>
                    <count group_id="O4" value="199"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.2" spread="24.3"/>
                    <measurement group_id="O2" value="-25.6" spread="26.9"/>
                    <measurement group_id="O3" value="-28.2" spread="27.1"/>
                    <measurement group_id="O4" value="-28.9" spread="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Estimate (Standard Error) of the adjusted difference from baseline to last post baseline value between treatment groups means: placebo minus GLPG1972 dose regimen using a MMRM including the fixed, categorical effects of treatment, region (Asia and Rest of the World), time and treatment-by-time interaction, as well as the continuous, fixed covariates of baseline and time-by-baseline interaction preceded by a Multiple Imputation step for participants without post-baseline measurement.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.705</p_value>
            <p_value_desc>Two-sided adjusted p-value taking into account Dunnett adjustment (to be compared to 0.05).</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-2.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.5</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.1</ci_lower_limit>
            <ci_upper_limit>2.7</ci_upper_limit>
            <estimate_desc>Two-sided 95% Confidence Interval of the estimate without Dunnett adjustment.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Estimate (Standard Error) of the adjusted difference from baseline to last post baseline value between treatment groups means: placebo minus GLPG1972 dose regimen using a MMRM including the fixed, categorical effects of treatment, region (Asia and Rest of the World), time and treatment-by-time interaction, as well as the continuous, fixed covariates of baseline and time-by-baseline interaction preceded by a Multiple Imputation step for participants without post-baseline measurement.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.243</p_value>
            <p_value_desc>Two-sided adjusted p-value taking into account Dunnett adjustment (to be compared to 0.05).</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-4.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.5</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.0</ci_lower_limit>
            <ci_upper_limit>0.8</ci_upper_limit>
            <estimate_desc>Two-sided 95% Confidence Interval of the estimate without Dunnett adjustment.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Estimate (Standard Error) of the adjusted difference from baseline to last post baseline value between treatment groups means: placebo minus GLPG1972 dose regimen using a MMRM including the fixed, categorical effects of treatment, region (Asia and Rest of the World), time and treatment-by-time interaction, as well as the continuous, fixed covariates of baseline and time-by-baseline interaction preceded by a Multiple Imputation step for participants without post-baseline measurement.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.949</p_value>
            <p_value_desc>Two-sided adjusted p-value taking into account Dunnett adjustment (to be compared to 0.05).</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-1.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.5</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.1</ci_lower_limit>
            <ci_upper_limit>3.9</ci_upper_limit>
            <estimate_desc>Two-sided 95% Confidence Interval of the estimate without Dunnett adjustment.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Patient Global Assessment (PGA) of Disease Activity as Measured by VAS to Week 52</title>
        <description>The participant was asked &quot;Considering all the ways in which your knee osteoarthritis affects you, please rate on this 100 mm scale how well you are doing today&quot;. The participants rated the disease activity by marking on a 100-mm VAS, with 0 being no pain and 100 being extreme pain. Higher score indicated higher disease activity.</description>
        <time_frame>Baseline, Week 52</time_frame>
        <population>Analysis was based on mRS. Overall number of participants analyzed included participants with available data of PGA score at baseline. Number of participants analyzed for change from baseline to Week 52 included participants with available data of PGA score at baseline and Week 52.</population>
        <group_list>
          <group group_id="O1">
            <title>GLPG1972 75 mg</title>
            <description>Participants received 1 film-coated tablet of GLPG1972 75 mg and 3 GLPG1972 matching placebo tablets, orally once daily for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>GLPG1972 150 mg</title>
            <description>Participants received 2 film-coated tablets of GLPG1972 75 mg (total dose 150 mg) and 2 GLPG1972 matching placebo tablets, orally once daily for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>GLPG1972 300 mg</title>
            <description>Participants received 4 film-coated tablets of GLPG1972 75 mg (total dose 300 mg), orally once daily for 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received 4 film-coated tablets of GLPG1972 matching placebo, orally once daily for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Patient Global Assessment (PGA) of Disease Activity as Measured by VAS to Week 52</title>
          <description>The participant was asked &quot;Considering all the ways in which your knee osteoarthritis affects you, please rate on this 100 mm scale how well you are doing today&quot;. The participants rated the disease activity by marking on a 100-mm VAS, with 0 being no pain and 100 being extreme pain. Higher score indicated higher disease activity.</description>
          <population>Analysis was based on mRS. Overall number of participants analyzed included participants with available data of PGA score at baseline. Number of participants analyzed for change from baseline to Week 52 included participants with available data of PGA score at baseline and Week 52.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="232"/>
                <count group_id="O2" value="230"/>
                <count group_id="O3" value="232"/>
                <count group_id="O4" value="233"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="232"/>
                    <count group_id="O2" value="230"/>
                    <count group_id="O3" value="232"/>
                    <count group_id="O4" value="233"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.1" spread="18.3"/>
                    <measurement group_id="O2" value="47.9" spread="19.0"/>
                    <measurement group_id="O3" value="49.4" spread="17.5"/>
                    <measurement group_id="O4" value="50.4" spread="19.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline to Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="191"/>
                    <count group_id="O2" value="187"/>
                    <count group_id="O3" value="178"/>
                    <count group_id="O4" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.4" spread="30.0"/>
                    <measurement group_id="O2" value="14.3" spread="30.7"/>
                    <measurement group_id="O3" value="14.1" spread="28.4"/>
                    <measurement group_id="O4" value="14.0" spread="31.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Estimate (Standard Error) of the adjusted difference from baseline to last post baseline value between treatment groups means: GLPG1972 dose regimen minus placebo using a MMRM including the fixed, categorical effects of treatment, region (Asia and Rest of the World), time and treatment-by-time interaction, as well as the continuous, fixed covariates of baseline and time-by-baseline interaction preceded by a Multiple Imputation step for participants without post-baseline measurement.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.890</p_value>
            <p_value_desc>Two-sided adjusted p-value taking into account Dunnett adjustment (to be compared to 0.05).</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>1.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.5</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.4</ci_lower_limit>
            <ci_upper_limit>6.3</ci_upper_limit>
            <estimate_desc>Two-sided 95% Confidence Interval of the estimate without Dunnett adjustment.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Estimate (Standard Error) of the adjusted difference from baseline to last post baseline value between treatment groups means: GLPG1972 dose regimen minus placebo using a MMRM including the fixed, categorical effects of treatment, region (Asia and Rest of the World), time and treatment-by-time interaction, as well as the continuous, fixed covariates of baseline and time-by-baseline interaction preceded by a Multiple Imputation step for participants without post-baseline measurement.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.682</p_value>
            <p_value_desc>Two-sided adjusted p-value taking into account Dunnett adjustment (to be compared to 0.05).</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-2.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.5</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.1</ci_lower_limit>
            <ci_upper_limit>2.6</ci_upper_limit>
            <estimate_desc>Two-sided 95% Confidence Interval of the estimate without Dunnett adjustment.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Estimate (Standard Error) of the adjusted difference from baseline to last post baseline value between treatment groups means: GLPG1972 dose regimen minus placebo using a MMRM including the fixed, categorical effects of treatment, region (Asia and Rest of the World), time and treatment-by-time interaction, as well as the continuous, fixed covariates of baseline and time-by-baseline interaction preceded by a Multiple Imputation step for participants without post-baseline measurement.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>1.000</p_value>
            <p_value_desc>Two-sided adjusted p-value taking into account Dunnett adjustment (to be compared to 0.05).</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.5</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.8</ci_lower_limit>
            <ci_upper_limit>5.0</ci_upper_limit>
            <estimate_desc>Two-sided 95% Confidence Interval of the estimate without Dunnett adjustment.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Were Responders Based on the Outcome Measures in Rheumatology - Osteoarthritis Research Society International (OMERACT-OARSI) Criteria</title>
        <description>OMERACT-OARSI criteria involves improvement based on WOMAC pain and function subscales and PGA. The responders according to OMERACT-OARSI criteria were participants who had:&#xD;
A high improvement in pain or in function ≥ 50% and absolute change ≥ 20, OR&#xD;
Improvement in at least 2 of the 3 following:&#xD;
Pain ≥ 20% and absolute change ≥ 10&#xD;
Function ≥ 20% and absolute change ≥ 10&#xD;
Patient's global assessment ≥ 20% and absolute change ≥ 10.&#xD;
WOMAC pain subscale score: range of 0 to 20, higher scores indicating more pain,&#xD;
WOMAC physical function subscale score: range of 0 to 68, higher scores indicating worse physical function),&#xD;
PGA: The participant was asked &quot;Considering all the ways in which your knee osteoarthritis affects you, please rate on this 100 mm scale how well you are doing today&quot;. The participants rated disease activity by marking on a 100-mm VAS, with 0 being no pain and 100 being extreme pain. Higher score indicated higher disease activity.</description>
        <time_frame>Week 52</time_frame>
        <population>Analysis was based on the mRS. Overall number of participants analyzed included participants with available data of WOMAC pain and function subscales and PGA at Week 52.</population>
        <group_list>
          <group group_id="O1">
            <title>GLPG1972 75 mg</title>
            <description>Participants received 1 film-coated tablet of GLPG1972 75 mg and 3 GLPG1972 matching placebo tablets, orally once daily for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>GLPG1972 150 mg</title>
            <description>Participants received 2 film-coated tablets of GLPG1972 75 mg (total dose 150 mg) and 2 GLPG1972 matching placebo tablets, orally once daily for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>GLPG1972 300 mg</title>
            <description>Participants received 4 film-coated tablets of GLPG1972 75 mg (total dose 300 mg), orally once daily for 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received 4 film-coated tablets of GLPG1972 matching placebo, orally once daily for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Were Responders Based on the Outcome Measures in Rheumatology - Osteoarthritis Research Society International (OMERACT-OARSI) Criteria</title>
          <description>OMERACT-OARSI criteria involves improvement based on WOMAC pain and function subscales and PGA. The responders according to OMERACT-OARSI criteria were participants who had:&#xD;
A high improvement in pain or in function ≥ 50% and absolute change ≥ 20, OR&#xD;
Improvement in at least 2 of the 3 following:&#xD;
Pain ≥ 20% and absolute change ≥ 10&#xD;
Function ≥ 20% and absolute change ≥ 10&#xD;
Patient's global assessment ≥ 20% and absolute change ≥ 10.&#xD;
WOMAC pain subscale score: range of 0 to 20, higher scores indicating more pain,&#xD;
WOMAC physical function subscale score: range of 0 to 68, higher scores indicating worse physical function),&#xD;
PGA: The participant was asked &quot;Considering all the ways in which your knee osteoarthritis affects you, please rate on this 100 mm scale how well you are doing today&quot;. The participants rated disease activity by marking on a 100-mm VAS, with 0 being no pain and 100 being extreme pain. Higher score indicated higher disease activity.</description>
          <population>Analysis was based on the mRS. Overall number of participants analyzed included participants with available data of WOMAC pain and function subscales and PGA at Week 52.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="189"/>
                <count group_id="O2" value="187"/>
                <count group_id="O3" value="176"/>
                <count group_id="O4" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125"/>
                    <measurement group_id="O2" value="119"/>
                    <measurement group_id="O3" value="103"/>
                    <measurement group_id="O4" value="127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Estimate (Standard Error of log [estimate]) of the adjusted odds ratio between GLPG1972 dose regimen and placebo: between the proportions of participants with response: placebo versus GLPG1972 dose regimen.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.991</p_value>
            <p_value_desc>Two-sided adjusted p-value taking into account Dunnett adjustment (to be compared to 0.05).</p_value_desc>
            <method>Logistic Model</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.05</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.21</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.70</ci_lower_limit>
            <ci_upper_limit>1.58</ci_upper_limit>
            <estimate_desc>Two-sided 95% Confidence Interval of the estimate without Dunnett adjustment.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Estimate (Standard Error of log [estimate]) of the adjusted odds ratio between GLPG1972 dose regimen and placebo: between the proportions of participants with response: placebo versus GLPG1972 dose regimen.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.992</p_value>
            <p_value_desc>Two-sided adjusted p-value taking into account Dunnett adjustment (to be compared to 0.05).</p_value_desc>
            <method>Logistic Model</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.95</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.21</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.64</ci_lower_limit>
            <ci_upper_limit>1.43</ci_upper_limit>
            <estimate_desc>Two-sided 95% Confidence Interval of the estimate without Dunnett adjustment.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Estimate (Standard Error of log [estimate]) of the adjusted odds ratio between GLPG1972 dose regimen and placebo: between the proportions of participants with response: placebo versus GLPG1972 dose regimen.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.653</p_value>
            <p_value_desc>Two-sided adjusted p-value taking into account Dunnett adjustment (to be compared to 0.05).</p_value_desc>
            <method>Logistic Model</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.82</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.21</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.55</ci_lower_limit>
            <ci_upper_limit>1.23</ci_upper_limit>
            <estimate_desc>Two-sided 95% Confidence Interval of the estimate without Dunnett adjustment.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Cartilage Thickness of the Total Tibiofemoral Compartment (tTFC) of the Target Knee by qMRI to Week 52</title>
        <description>Reduction of cartilage loss was measured by cartilage thickness of the tTFC of the target knee using qMRI.</description>
        <time_frame>Baseline, Week 52</time_frame>
        <population>Analysis was based on mRS. Overall number of participants analyzed included participants with available data of cartilage thickness of the tTFC of the target knee at baseline. Number of participants analyzed for change from baseline to Week 52 included participants with available data of cartilage thickness of the tTFC of the target knee at baseline and Week 52.</population>
        <group_list>
          <group group_id="O1">
            <title>GLPG1972 75 mg</title>
            <description>Participants received 1 film-coated tablet of GLPG1972 75 mg and 3 GLPG1972 matching placebo tablets, orally once daily for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>GLPG1972 150 mg</title>
            <description>Participants received 2 film-coated tablets of GLPG1972 75 mg (total dose 150 mg) and 2 GLPG1972 matching placebo tablets, orally once daily for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>GLPG1972 300 mg</title>
            <description>Participants received 4 film-coated tablets of GLPG1972 75 mg (total dose 300 mg), orally once daily for 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received 4 film-coated tablets of GLPG1972 matching placebo, orally once daily for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Cartilage Thickness of the Total Tibiofemoral Compartment (tTFC) of the Target Knee by qMRI to Week 52</title>
          <description>Reduction of cartilage loss was measured by cartilage thickness of the tTFC of the target knee using qMRI.</description>
          <population>Analysis was based on mRS. Overall number of participants analyzed included participants with available data of cartilage thickness of the tTFC of the target knee at baseline. Number of participants analyzed for change from baseline to Week 52 included participants with available data of cartilage thickness of the tTFC of the target knee at baseline and Week 52.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="232"/>
                <count group_id="O2" value="229"/>
                <count group_id="O3" value="231"/>
                <count group_id="O4" value="234"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="232"/>
                    <count group_id="O2" value="229"/>
                    <count group_id="O3" value="231"/>
                    <count group_id="O4" value="234"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.49218" spread="1.02749"/>
                    <measurement group_id="O2" value="6.57424" spread="1.02706"/>
                    <measurement group_id="O3" value="6.51256" spread="0.97704"/>
                    <measurement group_id="O4" value="6.45879" spread="1.01774"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline to Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="162"/>
                    <count group_id="O2" value="158"/>
                    <count group_id="O3" value="150"/>
                    <count group_id="O4" value="172"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.03572" spread="0.17673"/>
                    <measurement group_id="O2" value="-0.02401" spread="0.20766"/>
                    <measurement group_id="O3" value="-0.01678" spread="0.20934"/>
                    <measurement group_id="O4" value="-0.06447" spread="0.23480"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Estimate (Standard Error) of the adjusted difference from baseline to last post baseline value between treatment groups means: placebo minus GLPG1972 dose regimen using a MMRM including the fixed, categorical effects of treatment, region (Asia and Rest of the World), time and treatment-by-time interaction, as well as the continuous, fixed covariates of baseline and time-by-baseline interaction preceded by a Multiple Imputation step for participants without post-baseline measurement.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.193</p_value>
            <p_value_desc>Two-sided adjusted p-value taking into account Dunnett adjustment (to be compared to 0.05).</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.03779</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.02156</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.00448</ci_lower_limit>
            <ci_upper_limit>0.08005</ci_upper_limit>
            <estimate_desc>Two-sided 95% Confidence Interval of the estimate without Dunnett adjustment.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Estimate (Standard Error) of the adjusted difference from baseline to last post baseline value between treatment groups means: placebo minus GLPG1972 dose regimen using a MMRM including the fixed, categorical effects of treatment, region (Asia and Rest of the World), time and treatment-by-time interaction, as well as the continuous, fixed covariates of baseline and time-by-baseline interaction preceded by a Multiple Imputation step for participants without post-baseline measurement.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.256</p_value>
            <p_value_desc>Two-sided adjusted p-value taking into account Dunnett adjustment (to be compared to 0.05).</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.03580</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.02235</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.00801</ci_lower_limit>
            <ci_upper_limit>0.07962</ci_upper_limit>
            <estimate_desc>Two-sided 95% Confidence Interval of the estimate without Dunnett adjustment.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Estimate (Standard Error) of the adjusted difference from baseline to last post baseline value between treatment groups means: placebo minus GLPG1972 dose regimen using a MMRM including the fixed, categorical effects of treatment, region (Asia and Rest of the World), time and treatment-by-time interaction, as well as the continuous, fixed covariates of baseline and time-by-baseline interaction preceded by a Multiple Imputation step for participants without post-baseline measurement.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.201</p_value>
            <p_value_desc>Two-sided adjusted p-value taking into account Dunnett adjustment (to be compared to 0.05).</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.03884</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.02243</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.00514</ci_lower_limit>
            <ci_upper_limit>0.08281</ci_upper_limit>
            <estimate_desc>Two-sided 95% Confidence Interval of the estimate without Dunnett adjustment.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Bone Area of the Medial Femoral Condyle Surface of the Target Knee by qMRI to Week 28</title>
        <time_frame>Baseline, Week 28</time_frame>
        <population>Analysis was based on mRS. Overall number of participants analyzed included participants with available data of bone area of the medial femoral condyle surface of the target knee at baseline. Number of participants analyzed for change from baseline to Week 28 included participants with available data of bone area of the medial femoral condyle surface of the target knee at baseline and Week 28.</population>
        <group_list>
          <group group_id="O1">
            <title>GLPG1972 75 mg</title>
            <description>Participants received 1 film-coated tablet of GLPG1972 75 mg and 3 GLPG1972 matching placebo tablets, orally once daily for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>GLPG1972 150 mg</title>
            <description>Participants received 2 film-coated tablets of GLPG1972 75 mg (total dose 150 mg) and 2 GLPG1972 matching placebo tablets, orally once daily for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>GLPG1972 300 mg</title>
            <description>Participants received 4 film-coated tablets of GLPG1972 75 mg (total dose 300 mg), orally once daily for 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received 4 film-coated tablets of GLPG1972 matching placebo, orally once daily for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Bone Area of the Medial Femoral Condyle Surface of the Target Knee by qMRI to Week 28</title>
          <population>Analysis was based on mRS. Overall number of participants analyzed included participants with available data of bone area of the medial femoral condyle surface of the target knee at baseline. Number of participants analyzed for change from baseline to Week 28 included participants with available data of bone area of the medial femoral condyle surface of the target knee at baseline and Week 28.</population>
          <units>mm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="234"/>
                <count group_id="O2" value="229"/>
                <count group_id="O3" value="232"/>
                <count group_id="O4" value="234"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="234"/>
                    <count group_id="O2" value="229"/>
                    <count group_id="O3" value="232"/>
                    <count group_id="O4" value="234"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2343.32026" spread="371.23246"/>
                    <measurement group_id="O2" value="2346.17547" spread="373.46086"/>
                    <measurement group_id="O3" value="2354.77368" spread="385.91599"/>
                    <measurement group_id="O4" value="2333.67525" spread="362.46041"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline to Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="202"/>
                    <count group_id="O2" value="191"/>
                    <count group_id="O3" value="190"/>
                    <count group_id="O4" value="210"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.21893" spread="31.81812"/>
                    <measurement group_id="O2" value="11.11178" spread="33.14557"/>
                    <measurement group_id="O3" value="7.63991" spread="33.60899"/>
                    <measurement group_id="O4" value="11.43549" spread="29.60810"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Estimate (Standard Error) of the adjusted difference from baseline to last post baseline value between treatment groups means: Placebo minus GLPG1972 dose regimen using an analysis of covariance (ANCOVA) including the factors treatment and region with baseline as covariate and no interaction, after a Multiple Imputation for missing data.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.627</p_value>
            <p_value_desc>Two-sided adjusted p-value taking into account Dunnett adjustment (to be compared to 0.05).</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>3.12394</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.13671</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.02464</ci_lower_limit>
            <ci_upper_limit>9.27252</ci_upper_limit>
            <estimate_desc>Two-sided 95% Confidence Interval of the estimate without Dunnett adjustment.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Estimate (Standard Error) of the adjusted difference from baseline to last post baseline value between treatment groups means: Placebo minus GLPG1972 dose regimen using an ANCOVA including the factors treatment and region with baseline as covariate and no interaction, after a Multiple Imputation for missing data.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.998</p_value>
            <p_value_desc>Two-sided adjusted p-value taking into account Dunnett adjustment (to be compared to 0.05).</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.46842</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.21111</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.82659</ci_lower_limit>
            <ci_upper_limit>6.76343</ci_upper_limit>
            <estimate_desc>Two-sided 95% Confidence Interval of the estimate without Dunnett adjustment.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Estimate (Standard Error) of the adjusted difference from baseline to last post baseline value between treatment groups means: Placebo minus GLPG1972 dose regimen using an ANCOVA including the factors treatment and region with baseline as covariate and no interaction, after a Multiple Imputation for missing data.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.449</p_value>
            <p_value_desc>Two-sided adjusted p-value taking into account Dunnett adjustment (to be compared to 0.05).</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>4.11756</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.27590</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.30536</ci_lower_limit>
            <ci_upper_limit>10.54049</ci_upper_limit>
            <estimate_desc>Two-sided 95% Confidence Interval of the estimate without Dunnett adjustment.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Bone Area of the Medial Femoral Condyle Surface of the Target Knee by qMRI to Week 52</title>
        <time_frame>Baseline, Week 52</time_frame>
        <population>Analysis was based on mRS. Overall number of participants analyzed included participants with available data of bone area of the medial femoral condyle surface of the target knee at baseline. Number of participants analyzed for change from baseline to Week 52 included participants with available data of bone area of the medial femoral condyle surface of the target knee at baseline and Week 52.</population>
        <group_list>
          <group group_id="O1">
            <title>GLPG1972 75 mg</title>
            <description>Participants received 1 film-coated tablet of GLPG1972 75 mg and 3 GLPG1972 matching placebo tablets, orally once daily for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>GLPG1972 150 mg</title>
            <description>Participants received 2 film-coated tablets of GLPG1972 75 mg (total dose 150 mg) and 2 GLPG1972 matching placebo tablets, orally once daily for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>GLPG1972 300 mg</title>
            <description>Participants received 4 film-coated tablets of GLPG1972 75 mg (total dose 300 mg), orally once daily for 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received 4 film-coated tablets of GLPG1972 matching placebo, orally once daily for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Bone Area of the Medial Femoral Condyle Surface of the Target Knee by qMRI to Week 52</title>
          <population>Analysis was based on mRS. Overall number of participants analyzed included participants with available data of bone area of the medial femoral condyle surface of the target knee at baseline. Number of participants analyzed for change from baseline to Week 52 included participants with available data of bone area of the medial femoral condyle surface of the target knee at baseline and Week 52.</population>
          <units>mm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="234"/>
                <count group_id="O2" value="229"/>
                <count group_id="O3" value="232"/>
                <count group_id="O4" value="234"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="234"/>
                    <count group_id="O2" value="229"/>
                    <count group_id="O3" value="232"/>
                    <count group_id="O4" value="234"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2343.32026" spread="371.23246"/>
                    <measurement group_id="O2" value="2346.17547" spread="373.46086"/>
                    <measurement group_id="O3" value="2354.77368" spread="385.91599"/>
                    <measurement group_id="O4" value="2333.67525" spread="362.46041"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline to Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="162"/>
                    <count group_id="O2" value="160"/>
                    <count group_id="O3" value="154"/>
                    <count group_id="O4" value="172"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.45592" spread="31.22629"/>
                    <measurement group_id="O2" value="22.06801" spread="42.85848"/>
                    <measurement group_id="O3" value="20.78279" spread="34.96462"/>
                    <measurement group_id="O4" value="18.08990" spread="35.93650"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Estimate (Standard Error) of the adjusted difference from baseline to last post baseline value between treatment groups means: placebo minus GLPG1972 dose regimen using a MMRM including the fixed, categorical effects of treatment, region (Asia and Rest of the World), time and treatment-by-time interaction, as well as the continuous, fixed covariates of baseline and time-by-baseline interaction preceded by a Multiple Imputation step for participants without post-baseline measurement.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.789</p_value>
            <p_value_desc>Two-sided adjusted p-value taking into account Dunnett adjustment (to be compared to 0.05)</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>2.84781</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.75674</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.51643</ci_lower_limit>
            <ci_upper_limit>10.21205</ci_upper_limit>
            <estimate_desc>Two-sided 95% Confidence Interval of the estimate without Dunnett adjustment.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Estimate (Standard Error) of the adjusted difference from baseline to last post baseline value between treatment groups means: placebo minus GLPG1972 dose regimen using a MMRM including the fixed, categorical effects of treatment, region (Asia and Rest of the World), time and treatment-by-time interaction, as well as the continuous, fixed covariates of baseline and time-by-baseline interaction preceded by a Multiple Imputation step for participants without post-baseline measurement.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.661</p_value>
            <p_value_desc>Two-sided adjusted p-value taking into account Dunnett adjustment (to be compared to 0.05).</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-3.64759</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.84747</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.19071</ci_lower_limit>
            <ci_upper_limit>3.89553</ci_upper_limit>
            <estimate_desc>Two-sided 95% Confidence Interval of the estimate without Dunnett adjustment.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Estimate (Standard Error) of the adjusted difference from baseline to last post baseline value between treatment groups means: placebo minus GLPG1972 dose regimen using a MMRM including the fixed, categorical effects of treatment, region (Asia and Rest of the World), time and treatment-by-time interaction, as well as the continuous, fixed covariates of baseline and time-by-baseline interaction preceded by a Multiple Imputation step for participants without post-baseline measurement.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.843</p_value>
            <p_value_desc>Two-sided adjusted p-value taking into account Dunnett adjustment (to be compared to 0.05).</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-2.55176</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.81987</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.04053</ci_lower_limit>
            <ci_upper_limit>4.93701</ci_upper_limit>
            <estimate_desc>Two-sided 95% Confidence Interval of the estimate without Dunnett adjustment.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Joint Space Width (JSW) of the Target Knee to Week 52</title>
        <description>The JSW is the space measured between the 2 bones in the knee joint and this is assessed by x-ray.</description>
        <time_frame>Baseline, Week 52</time_frame>
        <population>Analysis was based on mRS. Overall number of participants analyzed included participants with available data of JSW at baseline. Number of participants analyzed for change from baseline to Week 52 included participants with available data of JSW at baseline and Week 52.</population>
        <group_list>
          <group group_id="O1">
            <title>GLPG1972 75 mg</title>
            <description>Participants received 1 film-coated tablet of GLPG1972 75 mg and 3 GLPG1972 matching placebo tablets, orally once daily for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>GLPG1972 150 mg</title>
            <description>Participants received 2 film-coated tablets of GLPG1972 75 mg (total dose 150 mg) and 2 GLPG1972 matching placebo tablets, orally once daily for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>GLPG1972 300 mg</title>
            <description>Participants received 4 film-coated tablets of GLPG1972 75 mg (total dose 300 mg), orally once daily for 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received 4 film-coated tablets of GLPG1972 matching placebo, orally once daily for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Joint Space Width (JSW) of the Target Knee to Week 52</title>
          <description>The JSW is the space measured between the 2 bones in the knee joint and this is assessed by x-ray.</description>
          <population>Analysis was based on mRS. Overall number of participants analyzed included participants with available data of JSW at baseline. Number of participants analyzed for change from baseline to Week 52 included participants with available data of JSW at baseline and Week 52.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="234"/>
                <count group_id="O2" value="230"/>
                <count group_id="O3" value="232"/>
                <count group_id="O4" value="233"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="234"/>
                    <count group_id="O2" value="230"/>
                    <count group_id="O3" value="232"/>
                    <count group_id="O4" value="233"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.504" spread="0.779"/>
                    <measurement group_id="O2" value="2.500" spread="0.783"/>
                    <measurement group_id="O3" value="2.577" spread="0.840"/>
                    <measurement group_id="O4" value="2.483" spread="0.859"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline to Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="169"/>
                    <count group_id="O2" value="163"/>
                    <count group_id="O3" value="155"/>
                    <count group_id="O4" value="179"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.087" spread="0.397"/>
                    <measurement group_id="O2" value="-0.167" spread="0.506"/>
                    <measurement group_id="O3" value="-0.113" spread="0.464"/>
                    <measurement group_id="O4" value="-0.174" spread="0.470"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Estimate (Standard Error) of the adjusted difference from baseline to last post baseline value between treatment groups means: GLPG1972 dose regimen minus placebo using an ANCOVA including the factors treatment and region with baseline as covariate and no interaction, after a Multiple Imputation for missing data.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.141</p_value>
            <p_value_desc>Two-sided adjusted p-value taking into account Dunnett adjustment (to be compared to 0.05).</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.0951</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0499</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0028</ci_lower_limit>
            <ci_upper_limit>0.1929</ci_upper_limit>
            <estimate_desc>Two-sided 95% Confidence Interval of the estimate without Dunnett adjustment.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Estimate (Standard Error) of the adjusted difference from baseline to last post baseline value between treatment groups means: GLPG1972 dose regimen minus placebo using an ANCOVA including the factors treatment and region with baseline as covariate and no interaction, after a Multiple Imputation for missing data.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.981</p_value>
            <p_value_desc>Two-sided adjusted p-value taking into account Dunnett adjustment (to be compared to 0.05).</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.0158</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0519</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0861</ci_lower_limit>
            <ci_upper_limit>0.1177</ci_upper_limit>
            <estimate_desc>Two-sided 95% Confidence Interval of the estimate without Dunnett adjustment.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Estimate (Standard Error) of the adjusted difference from baseline to last post baseline value between treatment groups means: GLPG1972 dose regimen minus placebo using an ANCOVA including the factors treatment and region with baseline as covariate and no interaction, after a Multiple Imputation for missing data.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.349</p_value>
            <p_value_desc>Two-sided adjusted p-value taking into account Dunnett adjustment (to be compared to 0.05).</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.0753</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0529</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0286</ci_lower_limit>
            <ci_upper_limit>0.1792</ci_upper_limit>
            <estimate_desc>Two-sided 95% Confidence Interval of the estimate without Dunnett adjustment.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Have Used at Least 1 Systemic Analgesic During the Study</title>
        <description>Systemic analgesics included anti-inflammatory and anti-rheumatic products; analgesics; anti-diarrheals, intestinal, anti-inflammatory/anti-infective agents; and drugs for functional gastrointestinal disorders.</description>
        <time_frame>Baseline up to Week 52</time_frame>
        <population>Analysis was based on mRS.</population>
        <group_list>
          <group group_id="O1">
            <title>GLPG1972 75 mg</title>
            <description>Participants received 1 film-coated tablet of GLPG1972 75 mg and 3 GLPG1972 matching placebo tablets, orally once daily for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>GLPG1972 150 mg</title>
            <description>Participants received 2 film-coated tablets of GLPG1972 75 mg (total dose 150 mg) and 2 GLPG1972 matching placebo tablets, orally once daily for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>GLPG1972 300 mg</title>
            <description>Participants received 4 film-coated tablets of GLPG1972 75 mg (total dose 300 mg), orally once daily for 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received 4 film-coated tablets of GLPG1972 matching placebo, orally once daily for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Have Used at Least 1 Systemic Analgesic During the Study</title>
          <description>Systemic analgesics included anti-inflammatory and anti-rheumatic products; analgesics; anti-diarrheals, intestinal, anti-inflammatory/anti-infective agents; and drugs for functional gastrointestinal disorders.</description>
          <population>Analysis was based on mRS.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="234"/>
                <count group_id="O2" value="231"/>
                <count group_id="O3" value="233"/>
                <count group_id="O4" value="234"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Participants with at least one treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="216"/>
                    <measurement group_id="O2" value="213"/>
                    <measurement group_id="O3" value="211"/>
                    <measurement group_id="O4" value="212"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-inflammatory and anti-rheumatic products</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="173"/>
                    <measurement group_id="O2" value="167"/>
                    <measurement group_id="O3" value="180"/>
                    <measurement group_id="O4" value="178"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Analgesics</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="127"/>
                    <measurement group_id="O2" value="135"/>
                    <measurement group_id="O3" value="118"/>
                    <measurement group_id="O4" value="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-diarrheals, intestinal anti-inflammatory/anti-infective agents</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drugs for functional gastrointestinal disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Concentrations of GLPG1972</title>
        <time_frame>Pre-dose at Weeks 4, 12, and 52; Pre-dose and one post-dose sample (2-4 hours interval) at Week 28; one post dose sample (interval 4-8 hours) at Week 40</time_frame>
        <population>Overall number of participants included participants with available data for plasma concentrations of GLPG1972. Number of participants analyzed included participants with available data for plasma concentrations of GLPG1972 at individual timepoints. As participants in the placebo arm did not receive GLPG1972, measurement of plasma concentrations of GLPG1972 for placebo arm is not applicable.</population>
        <group_list>
          <group group_id="O1">
            <title>GLPG1972 75 mg</title>
            <description>Participants received 1 film-coated tablet of GLPG1972 75 mg and 3 GLPG1972 matching placebo tablets, orally once daily for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>GLPG1972 150 mg</title>
            <description>Participants received 2 film-coated tablets of GLPG1972 75 mg (total dose 150 mg) and 2 GLPG1972 matching placebo tablets, orally once daily for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>GLPG1972 300 mg</title>
            <description>Participants received 4 film-coated tablets of GLPG1972 75 mg (total dose 300 mg), orally once daily for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentrations of GLPG1972</title>
          <population>Overall number of participants included participants with available data for plasma concentrations of GLPG1972. Number of participants analyzed included participants with available data for plasma concentrations of GLPG1972 at individual timepoints. As participants in the placebo arm did not receive GLPG1972, measurement of plasma concentrations of GLPG1972 for placebo arm is not applicable.</population>
          <units>μg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="217"/>
                <count group_id="O2" value="210"/>
                <count group_id="O3" value="194"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4: Pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="217"/>
                    <count group_id="O2" value="210"/>
                    <count group_id="O3" value="194"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.445" spread="0.319"/>
                    <measurement group_id="O2" value="1" spread="0.946"/>
                    <measurement group_id="O3" value="2.013" spread="1.468"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="208"/>
                    <count group_id="O2" value="203"/>
                    <count group_id="O3" value="192"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.474" spread="0.685"/>
                    <measurement group_id="O2" value="0.952" spread="0.794"/>
                    <measurement group_id="O3" value="1.788" spread="1.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28: Pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="197"/>
                    <count group_id="O2" value="188"/>
                    <count group_id="O3" value="178"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.457" spread="0.409"/>
                    <measurement group_id="O2" value="0.857" spread="0.696"/>
                    <measurement group_id="O3" value="1.714" spread="1.206"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28: 2-4 hours post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="199"/>
                    <count group_id="O2" value="188"/>
                    <count group_id="O3" value="182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.399" spread="0.668"/>
                    <measurement group_id="O2" value="2.609" spread="1.022"/>
                    <measurement group_id="O3" value="4.764" spread="1.912"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40: 4-8 hours post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="187"/>
                    <count group_id="O2" value="184"/>
                    <count group_id="O3" value="176"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.54" spread="0.678"/>
                    <measurement group_id="O2" value="3.13" spread="1.2"/>
                    <measurement group_id="O3" value="5.664" spread="2.425"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: Pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="159"/>
                    <count group_id="O2" value="151"/>
                    <count group_id="O3" value="147"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.603" spread="0.6"/>
                    <measurement group_id="O2" value="1.12" spread="1.048"/>
                    <measurement group_id="O3" value="2.132" spread="1.597"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment-emergent Adverse Event (TEAE)</title>
        <description>TEAEs were defined as all adverse events (AEs) that occurred:&#xD;
between first IMP intake date (included) and last visit of participant, or&#xD;
before first IMP intake date and that worsened (in terms of intensity) or became serious according to investigator opinion between first IMP intake date (included) and last visit of participant.&#xD;
Number of participants with at least 1 TEAE (serious or non-serious) are reported.</description>
        <time_frame>Baseline up to 2-weeks after last dose of IMP (up to Week 54)</time_frame>
        <population>Safety Set: All participants having taken at least one dose of IMP.</population>
        <group_list>
          <group group_id="O1">
            <title>GLPG1972 75 mg</title>
            <description>Participants received 1 film-coated tablet of GLPG1972 75 mg and 3 GLPG1972 matching placebo tablets, orally once daily for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>GLPG1972 150 mg</title>
            <description>Participants received 2 film-coated tablets of GLPG1972 75 mg (total dose 150 mg) and 2 GLPG1972 matching placebo tablets, orally once daily for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>GLPG1972 300 mg</title>
            <description>Participants received 4 film-coated tablets of GLPG1972 75 mg (total dose 300 mg), orally once daily for 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received 4 film-coated tablets of GLPG1972 matching placebo, orally once daily for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-emergent Adverse Event (TEAE)</title>
          <description>TEAEs were defined as all adverse events (AEs) that occurred:&#xD;
between first IMP intake date (included) and last visit of participant, or&#xD;
before first IMP intake date and that worsened (in terms of intensity) or became serious according to investigator opinion between first IMP intake date (included) and last visit of participant.&#xD;
Number of participants with at least 1 TEAE (serious or non-serious) are reported.</description>
          <population>Safety Set: All participants having taken at least one dose of IMP.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="234"/>
                <count group_id="O2" value="231"/>
                <count group_id="O3" value="232"/>
                <count group_id="O4" value="234"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="174"/>
                    <measurement group_id="O2" value="177"/>
                    <measurement group_id="O3" value="174"/>
                    <measurement group_id="O4" value="174"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline up to 2-weeks after last dose of IMP (up to Week 54)</time_frame>
      <desc>TEAEs were defined as all AEs that occurred:&#xD;
between first IMP intake date (included) and last visit of participant, or&#xD;
before first IMP intake date and that worsened (in terms of intensity) or became serious according to investigator opinion between first IMP intake date (included) and last visit of participant.&#xD;
Analysis was based on the safety set. All serious AEs are reported, TEAEs are reported at a threshold of 3%.</desc>
      <group_list>
        <group group_id="E1">
          <title>GLPG1972 75 mg</title>
          <description>Participants received 1 film-coated tablet of GLPG1972 75 mg and 3 GLPG1972 matching placebo tablets, orally once daily for 52 weeks.</description>
        </group>
        <group group_id="E2">
          <title>GLPG1972 150 mg</title>
          <description>Participants received 2 film-coated tablets of GLPG1972 75 mg (total dose 150 mg) and 2 GLPG1972 matching placebo tablets, orally once daily for 52 weeks.</description>
        </group>
        <group group_id="E3">
          <title>GLPG1972 300 mg</title>
          <description>Participants received 4 film-coated tablets of GLPG1972 75 mg (total dose 300 mg), orally once daily for 52 weeks.</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Participants received 4 film-coated tablets of GLPG1972 matching placebo, orally once daily for 52 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (23.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="232"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="234"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Myocarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="234"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="234"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Angle closure glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Macular degeneration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="234"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Peritoneal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Abdominal incarcerated hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="234"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="234"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Drug-induced liver injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="234"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>COVID-19</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Appendiceal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Burn infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="234"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Face injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="234"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="234"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="232"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Myopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="234"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Prostate cancer stage II</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Invasive ductal breast carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Invasive papillary breast carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Endometrial adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Malignant melanoma in situ</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Glottis carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Intraductal proliferative breast lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="234"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cervical cord compression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="234"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression suicidal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="234"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Ureterolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="234"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="234"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="234"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="234"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>MedDRA (23.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="114" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="124" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="105" subjects_at_risk="232"/>
                <counts group_id="E4" subjects_affected="130" subjects_at_risk="234"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="232"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="232"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="234"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="232"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="234"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="232"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="232"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="232"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="232"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="232"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="234"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="232"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="232"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="234"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="232"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="232"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="232"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="232"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="232"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="234"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="232"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="234"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="232"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="232"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="232"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="232"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="232"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="232"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="234"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="232"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="234"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="231"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="232"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="234"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The sponsor must review and approve any results of the study or abstracts for professional meetings prepared by the investigator(s). Published data must not compromise the objectives of the study. Data from individual study centers in multicenter studies must not be published separately.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Galapagos Medical Information</name_or_title>
      <organization>Galapagos NV</organization>
      <phone>+32 15342900</phone>
      <email>medicalinfo@glpg.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

